Advertisement

Topics

Latest "Xoma Novartis Partner Beta MAbs Related" News Stories

05:08 EDT 20th July 2018 | BioPortfolio

Here are the most relevant search results for "Xoma Novartis Partner Beta MAbs Related" found in our extensive news archives from over 250 global news sources.

More Information about Xoma Novartis Partner Beta MAbs Related on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Xoma Novartis Partner Beta MAbs Related for you to read. Along with our medical data and news we also list Xoma Novartis Partner Beta MAbs Related Clinical Trials, which are updated daily. BioPortfolio also has a large database of Xoma Novartis Partner Beta MAbs Related Companies for you to search.

Showing "Xoma Novartis Partner Beta MAbs Related" News Articles 1–25 of 12,000+

Friday 20th July 2018

Feasibility and acceptability of brief behavioral therapy for cancer-related insomnia: effects on insomnia and circadian rhythm during chemotherapy: a phase II randomised multicentre control trial


WuXi STA and Antengene Sign Development and Manufacturing Agreement

SHANGHAI, July 20, 2018 /PRNewswire/ -- STA Pharmaceutical Co., Ltd., (WuXi STA) - a subsidiary of WuXi AppTec - and Antengene Corporation, a biopharmaceutical company, recently announced a strategic partnership for the CMC development and manufacturing of innovative oncology drugs. Under the terms of the collaboration, WuXi STA will provide Antengene an integrated solution in process R&...

Roche to present new data demonstrating the breadth and depth of its Alzheimer's programme at the upcoming Alzheimer's Association International Conference

F. Hoffmann-La Roche Ltd / Roche to present new data demonstrating the breadth and depth of its Alzheimer's programme at the upcoming Alzheimer's Association International Conference . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Late-breaking Phase II exploratory analysis of investiga...


FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease

F. Hoffmann-La Roche Ltd / FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Basel, 20 July 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) ann...

Novartis to pay EUR95m to Galapagos and MorphoSys for skin drug rights

Novartis has agreed to make an upfront payment of EUR95m to Galapagos and MorphoSys to in-license IL-17C compound for atopic dermatitis.

Liver disease deaths spike among young Americans – KSAT San Antonio

KSAT San AntonioLiver disease deaths spike among young AmericansKSAT San Antonio(CNN) - More Americans, especially young people, are dying of conditions related to liver cirrhosis, according to a new study. After adjusting for age and other factors, the study -- published Wednesday in the BMJ -- found that deaths in the United ...A Spike In Liver Disease Deaths Among Young Adults Fueled By Alcohol...

India sees major reductions in HIV infections: UN report – Times of India

Financial ExpressIndia sees major reductions in HIV infections: UN reportTimes of IndiaUNITED NATIONS: India saw a major reduction in the number of new HIV infections, AIDS-related deaths and people living with HIV from 2010 to 2017 on the back of sustained and focussed efforts, according to a UN report which warned that the epidemic ...'Dangerous complacency' looms over world AIDS meetingJournald...

Genentech to Present New Data Demonstrating the Breadth and Depth of Its Alzheimer’s Program at the Upcoming Alzheimer's Association International Conference (AAIC)

Late-breaking Phase II exploratory analysis of investigational crenezumab to show impact on beta amyloid oligomer levels in cerebral spinal fluid (CSF) Two-year open-label extension updates for investigational gantenerumab will include data on effects of higher doses in reducing amyloid PET load and long-term safety ...

Liver disease deaths spike among young Americans – KKOH

KKOHLiver disease deaths spike among young AmericansKKOH(CNN) – More Americans, especially young people, are dying of conditions related to liver cirrhosis, according to a new study. After adjusting for age and other factors, the study — published Wednesday in the BMJ — found that deaths in the United ...Alcohol-related cirrhosis mortality on the rise among young adultsNews-Medical.netDeath ...

Novartis: skin in the game

The shift towards finding new treatments is a worthy gamble

Thursday 19th July 2018

Shanghai Green Valley Reports Positive Results from Phase III Trial of Alzheimer's Drug

Shanghai Green Valley Pharma reported positive results from a China Phase III trial of its Alzheimer's treatment in patients with mild-to-moderate disease. The double-blinded 36-week trial met its primary endpoint, showing "significantly improved" scores on assessment scales, though the company did not disclose specific results. The drug, GV-971, is an oligosaccharide molecule extracted from seawe...

Amazon Hurricane Heading Towards Indian Pharma?

Think Amazon, think disruption, and that’s exactly what could be in store if the online retail juggernaut goes through with...    

[Comment] New strategies for inpatients with HIV and tuberculosis

Decreasing tuberculosis-related mortality—particularly in people living with HIV infection, who account for 22% of all tuberculosis deaths—is a pressing global health concern.1 Tuberculosis cascade-of-care analyses show that diagnosis is the weakest link.2,3 There is an urgent need for a non-sputum based, point-of-care diagnostic test for tuberculosis, particularly for groups such as those liv...

Vivli Nonprofit Hopes To Be One-Stop Shop For Clinical Trial Data

GlaxoSmithKline, Pfizer, and Biogen are among those participating in new data-sharing and analytics platform; 2,500 trials currently available to researchers.   

Takeda/Ovid Broaden Pioneering CH24H Inhibitor To Rare Epilepsies

Takeda and partner Ovid are planning new trials in rare pediatric indications for their first-in-class epilepsy drug, including in the...  

Merck's New Pricing Pledge Shows Style Over Substance

A 60% price reduction on hepatitis C drug Zepatier sounds impressive, but the drug has been declining and the HCV...   

Drug Importation Can Be Triggered By 'Excessive' Price Increases; Now US FDA Has To Decide What That Means

Did FDA Commissioner Scott Gottlieb and HHS Secretary Alex Azar have a change of heart on importation? Or are they...   

Who Wants To Be 'Essential'? US FDA Considers Critical Drugs List

To address chronic shortages, FDA may create list of 'essential' drugs, but will suppliers of those products be happy to...   

Expert Warns Of Looming 'Capacity Crunch' For New Cell And Gene Therapy Products

Capacity shortages are looming for manufacturers wanting to develop and commercialize cell and gene therapy products over the next five...   

Allergan's Abicipar Effective With Fewer Injections, But More Inflammation In AMD

Allergan and Molecular Partners said dosing of the VEGF inhibitor every eight or 12 weeks was non-inferior to Lucentis every...   

Aetna to Announce Second-Quarter 2018 Results

Aetna (NYSE: AET) today announced that second-quarter 2018 results will be made public on Thursday, August 2, at 6:30 a.m. ET. Given the pending transaction with CVS Health, Aetna will not host a conference call in conjunction with its earnings release. About AetnaAetna is one of the nation's leading diversified health care benefits compani...

Huami Corporation Enters Partnership with PAI Health, to Offer Health Risk Services to the Insurance Industry

BEIJING, July 19, 2018 /PRNewswire/ -- Huami Corporation ("Huami" or the "Company") (NYSE: HMI), a biometric and activity data-driven company with significant expertise in smart wearable technology, today announced that it has signed a partnership agreement with PAI Health, a health technology software company. This partnership combines Huami's massive biometric database...

ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and Secretary

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Austin D. Kim has joined ACADIA as Executive Vice President, General Counsel and Secretary. He will report to Steve Da...

Exclusivity Period Allowed By OTC Monograph Reform Likely Up To Conference Committee

Next step for OTC monograph reform legislation is Senate consideration; market exclusivity periods are likely focus of House/Senate conference. Separate...   

Adding Multivitamins To SNAP Sprouts Or Wilts In Congress' Decision On Farm Bill

House appoints its farm bill conference committee members primarily from Agriculture Committee but also with reps from committees with oversight for...   


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks